Rituximab and other emerging monoclonal antibody therapies for lymphoma

Bibliography

• STASHENKO P, NADLER LM, HARDY R et al: Characterization of a human B lymphocyte-specific antigen. I Immunol. (1980) 125:1678–1685.
   PubMed Web of Science ®Google Scholar
• TOBINAI K, HIROSE M, YAMADA H et al.: Cellular origin of human lymphoid malignancies as based on immunologic analysis of membrane differentiation antigens. fpn. I Clin. amyl. (1982) 12:73–90.
   Web of Science ®Google Scholar
• ANDERSON KC, BATES MP, SLAUGHENHOUPT BL et al.: Expression of human B cell associated antigens on leukaemias and lymphomas: a model of human B cell differentiation. Blood (1984) 63: 1424–1433.
   Google Scholar
• PRESS OW, APPELBAUM F, LEDBETTER JA et al.: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood (1987) 69: 584–591.
   Google Scholar
• PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabelled-antibody therapy of B cell lymphoma with autologous bone marrow support. N Engl. I Med. (1993) 329:1219–1224.
   PubMed Web of Science ®Google Scholar
• •Innovative 131I-labelled radioirnmunotherapy of myeloablative doses.
   Google Scholar
• PRESS OW, EARY JF, APPELBAUM FR et al.: Phase II trial of 1-311-B1 (anti-CD 20)antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 346:336–340.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al.: Radioimmunotherapy of B cell lymphoma with [131I] antiBl (anti-CD20) antibody. N Engl. I Med. (1993) 329:459–465.
   PubMed Web of Science ®Google Scholar
• •Innovative 131I-labelled radioirnmunotherapy of non-myeloablative doses.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al.: Iodine-131: antiBl radioimmunotherapy for B cell lymphoma. Cilia. Oncol. (1996) 14:1974–1981.
   PubMed Web of Science ®Google Scholar
• KNOX SJ, GORIS ML, TRISLER K et al: Yttrium-90-labelled antiCD20 monoclonal antibody therapy of recurrent B cell lymphoma. Cilia. Cancer Res. (1996) 2:457–470.
   PubMed Web of Science ®Google Scholar
• •A Phase I trial of 90Y-labelled radioirnmunotherapy.
   Google Scholar
• HORNING SJ: Natural history of and therapy for the indolent nonHodgkin's lymphomas. Semin. Oncol. (1993) 20 (Suppl. 5):75–88.
   PubMed Web of Science ®Google Scholar
• •An excellent review on the treatment of indolent B-NHL.
   Google Scholar
• BIERMAN PJ, VOSE JM, ANDERSON JR et al.: High-dose therapy with autologous hematopoietic rescue for follicular low-grade nonHodgkin's lymphoma. I Cilia. Oncol. (1997) 15:445–450.
   PubMed Web of Science ®Google Scholar
• DANA BW, DAHLBERG S, NATHWANI BN et al.: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. Cilia. Oncol. (1993) 11:644–651.
   PubMed Web of Science ®Google Scholar
• BANKS P, CHAN J, CLEARY M et al: Mantle cell lymphoma: A proposal for unification of morphologic, immunologic and molecular data. Am. I Sorg. Patna (1992) 16:637–640.
   PubMed Web of Science ®Google Scholar
• WEISENBURGER DD, ARMITAGE JO: Mantle cell lymphoma: an entity comes of age. Blood(1996) 87: 4483–4494.
   Google Scholar
• NON-HODGKIN'S LYMPHOMA CLASSIFICATION PROJECT: A clinical evaluation of the International Lymphoma Study Group Classification of nonHodgkin's lymphoma. Blood (1997) 89: 3909–3918.
   Google Scholar
• YATABE Y, SUZUKI R, TOBINAI K et al: Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin Dl-negative MCL-like B cell lymphoma. Blood (2000) 95:2253–2261.
   PubMed Web of Science ®Google Scholar
• REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435–445.
   PubMed Web of Science ®Google Scholar
• ••The first paper of rituximab.
   Google Scholar
• MALONEY DG, LILES TM, CZERWINSKI DK et al.: Phase I clinical trial using escalating single-dose infusion of chimeric antiCD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma. Blood (1994) 84: 2457–2466.
   Google Scholar
• ••A Phase I study of rituximab in the US.
   Google Scholar
• CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumour targets. Nat. Med. (2000) 6:443–446.
   PubMed Web of Science ®Google Scholar
• TOBINAI K, KOBAYASHI Y, NARABAYASHI M et al.: Feasibility and pharmacokinetic study of a chimeric antiCD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B cell lymphoma. Ann. Oncol (1998) 9:527–534.
   PubMed Web of Science ®Google Scholar
• •A Japanese Phase I study of rituximab.
   Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, BODKIN D et al: IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed nonHodgkin's lymphoma. I Clio. Oncol (1997) 15:3266–3274.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (rituximab) antiCD20 antibody therapy in patients with relapsed low-grade nonHodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• IGARASHI T, KOBAYASHI Y, OGURA M et al.: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese Phase II study. Ann. Oncol (2002) 13:928–943.
   PubMed Web of Science ®Google Scholar
• •A pivotal Japanese Phase II study of rituximab for indolent B-NHL and MCL.
   Google Scholar
• TOBINAIK: Clinical trials of a mouse-human chimeric antiCD20 monoclonal antibody (rituximab) for B cell nonHodgkin's lymphoma in Japan. Cancer Chemother. Phamacol (2001) 48 (Suppl. 1):S85–S90.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, STEIN H et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood(1994) 84: 1361–1392.
   Google Scholar
• MACLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program.' Clio. Oncol (1998) 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• •A pivotal study of rituximab in the US.
   Google Scholar
• IGARASHI T, OHTSU T, FUJII H et al: retreatment of relapsed indolent B cell lymphoma with rituximab. kit. j Hematol (2001) 73:213–221.
   Web of Science ®Google Scholar
• •A Japanese retreatment study of rituximab.
   Google Scholar
• DAVIS TA, GRILLO-LOPEZ AJ, WHITE CA et al.: Rituximab antiCD20 monoclonal antibody therapy in nonHodgkin's lymphoma: Safety and efficacy of retreatment. Clio. Oncol (2000) 18:3135–3143.
   PubMed Web of Science ®Google Scholar
• •An American retreatment study of rituximab.
   Google Scholar
• IGARASHI T, ITOH K, KOBAYASHI Y et al.: Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B cell nonHodgkin's lymphoma. Proc. Am. Soc. Clio. Oncol (2002) 21:286a.
   Google Scholar
• •A Japanese Phase II study of rituximab for aggressive B-NHL.
   Google Scholar
• CHESON BD, HORNING SJ, COIFFIER B et al.: Report of an international workshop to standardize response criteria for nonHodgkin's lymphomas. " Clio. Oncol (1999) 17:1244–1253.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, HAIOUN C, KETTERER A et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study. Blood (1998) 92: 1927–1932.
   Google Scholar
• •A European Phase II study of rituximab for aggressive B-NHL.
   Google Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al: Treatment of patients with low-grade B cell lymphoma with the combination of chimeric antiCD20 monoclonal antibody and CHOP chemotherapy. " Clio. Oncol (1999) 17: 268–276.
   PubMed Web of Science ®Google Scholar
• •The first combination study of rituximab plus CHOP for indolent B-NHL.
   Google Scholar
• VOSE JM, LINK BK, GROSSBARD ML et al.: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive nonHodgkin's lymphoma.' Clio. Oncol (2001) 19:389–397.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl. I Med. (2002) 346:235–242.
   PubMed Web of Science ®Google Scholar
• ••An important Phase III study showing the superiority of rituximab plus CHOP to CHOP alone in untreated aggressive B-NHL.
   Google Scholar
• WITZIG TE, WHITE CA, WISEMAN GA et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B cell nonHodgkin's lymphoma. I Clio. Oncol (1999) 17:3793–3803.
   PubMed Web of Science ®Google Scholar
• ••A Phase I/II study of 9°Y-labelledradioimmunotherapy.
   Google Scholar
• WISEMAN GA, GORDON LI, MULTANI PS et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory nonHodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood (2002) 99:4336–4342.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labelled ibritumomab titixetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular or transformed B cell nonHodgkin's lymphoma. I Clio. Oncol (2002) 20:2453–2463.
   PubMed Web of Science ®Google Scholar
• •A comparative study showing the superiority of 9°Y-labelled radioimmunotherapy to rituximab.
   Google Scholar
• WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab titixetan radioimmunotherapy in patients with rituximab-refractory follicular nonHodgkin's lymphoma. I Clio. Oncol (2002) 20:3262–3269.
   PubMed Web of Science ®Google Scholar
• •An encouraging Phase II study showing the effectiveness of 90Y-labelled radioimmunotherapy in rituximab-refractory cases.
   Google Scholar
• HAINS WORTH JD, BURRIS III HA, MORRISSEY LH et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade nonHodgkin lymphoma. Blood (2000) 95:3052–3056.
   PubMed Web of Science ®Google Scholar
• •The first study of rituximab for untreated indolent B-NHL.
   Google Scholar
• COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD 20monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumour burden: clinical and molecular evaluation. Blood (2001) 97: 101–106.
   Google Scholar
• HOWARD 0 M, GRIBBEN JG, NEUBERG DS et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Clin. Oncol (2002) 20:1288–1294.
   Web of Science ®Google Scholar
• KHOURI IF, ROMANGUERA J, KANTARJIAN H et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. .1. Chit. Oncol (1998) 16:3803–3809.
   PubMed Web of Science ®Google Scholar
• BERINSTEIN NL, GRILLO-LOPEZ AJ,WHITE CA et al.: Association of serum Ritwdmab (IDEC-C2B8) concentration and antitumour response in the treatment of recurrent low-grade or follicular nonHodgkin's lymphoma. Ann. Oncol (1998) 9:995–1001.
   PubMed Web of Science ®Google Scholar
• BYRD JC, MURPHY T, HOWARD RS et al.: Rittiximab using a thrice-weekly dosing schedule in B cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Clin. Oncol (2001) 19:2153–2164.
   Web of Science ®Google Scholar
• O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rittiximab dose-escalation trial in chronic lymphocytic leukaemia. J. Clin. Oncol (2001) 19:2165–2170.
   PubMed Web of Science ®Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular nonHodgkin's lymphoma. Ann. Oncol (1999) 10:655–661.
   PubMed Web of Science ®Google Scholar
• MAGNI M, DI NICOLA M, DEVIZZI L et al.: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood (2000) 96:864–869.
   PubMed Web of Science ®Google Scholar
• VOSO MT, PANTEL G, WEIS M et al: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with nonHodgkin's lymphoma. Br. Haematol (2000) 109:729–735.
   PubMed Web of Science ®Google Scholar
• FLINN IW, O'DONNELL PV, GOODRICH A et al.: Immunotherapy with rituximab during peripheral blood stem cell transplantation for nonHodgkin's lymphoma. Biol. Blood Marrow Transplant. (2000) 6:628–632.
   PubMed Web of Science ®Google Scholar
• LAZZARINO M, ARCAINI L, BERNASCONI P et al.: A sequence of immunochemotherapy with Ritwdmab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma. Br. J. Haematol (2002) 116:229–235.
   PubMed Web of Science ®Google Scholar
• MORSCHHAUSER F, RECHER C, GALOIN S et al: Multicenter, Phase II trial to evaluate the efficacy and safety of rituximab in patients suffering from follicular nonHodgkin's lymphoma with residual minimal disease after autologous transplantation of hematopoietic stem cell (M39012 trial). Proc. Am. Soc. Chit. Oncol (2002) 21:267a (abstract #1066).
   Google Scholar
• FRIEDBERG JW, NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular nonHodgkin's lymphoma. Br. J. Haematol (2002) 117:828–834.
   PubMed Web of Science ®Google Scholar
• ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with rituximab in patients with B cell nonHodgkin lymphoma. Blood (2002) 99:67–74.
   PubMed Web of Science ®Google Scholar
• DAVIS TA, MALONEY DG, GRILLO-LOPEZ AJ et al.: Combination immunotherapy of relapsed or refractory low-grade or follicular nonHodgkin's lymphoma with rituximab and interferon-a-2a. Chit. Cancer Res. (2000) 6:2644–2652.
   Google Scholar
• VOSE JM, WAHL RL, SALEH M et al.: Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B cell nonHodgkin's lymphomas. Chit. Oncol (2000) 18:1316–1323.
   PubMed Web of Science ®Google Scholar
• •The first combination study of rituximab plus CHOP for aggressive B-NHL.
   Google Scholar
• KAMINSKI MS, ZELENETZ AD, PRESS OW et al.: Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B cell nonHodgkin's lymphomas. I Chit. Oncol (2001) 19:3918–3928.
   PubMed Web of Science ®Google Scholar
• •A pivotal study of 1311-labelled radioirnmunotherapy.
   Google Scholar
• LEONARD JP, COLEMAN M, SCHUSTER MW et al.: Immunotherapy of NHL with epratuzumab (anti-CD22 monoclonal antibody): Excellent tolerability with objective responses. Proc. Am. Soc. Chit. Oncol (2000) 19:17a (abstract #60).
   Google Scholar
• LEONARD JP, COLEMAN M, MATTHEWS JC et al: Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for nonHodgkin's lymphoma: Preliminary response data. Proc. Am. Soc. Clin. Oncol (2002) 21:266a (abstract #1060).
   Google Scholar
• KREITMAN RJ, WILSON WH, BERGERON K et al.: Efficacy of the antiCD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukaemia. N Engl. J. Med. (2001) 345:241–247.
   PubMed Web of Science ®Google Scholar
• ••An innovative trial of recombinantimmunotoxin.
   Google Scholar
• KREITMAN RJ, WILSON WH, ROBBINS D et al.: Responses in refractory hairy cell leukaemia to a recombinant immunotoxin. Blood (1999) 94:3340–3348.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, WILSON WH, WHITE JD et al.: Phase I trial of recombinant immunotoxin antiTac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Chit. Oncol (2000) 18:1622–1636.
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G et al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade nonHodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade nonHodgkin's Lymphoma. I Clin. Oncol (1998) 16:3257–3263.
   Web of Science ®Google Scholar
• OSTERBORG A, DYER MJ, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukaemia. J. Chit. Oncol (1997) 15:1567–1574.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood(2002) 99: 3554–3561.
   Google Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous antiCD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B cell chronic lymphocytic leukaemia (B-CLL). Blood (2002) 100:768–773.
   PubMed Web of Science ®Google Scholar
• LINK BK, WANG H, BYRD JC et al: Phase I study of Hu1D10 monoclonal antibody in patients with B cell lymphoma. Proc. Am. Soc. Chit. Oncol (2001) 20:284a (abstract #1135).
   Google Scholar
• ABHYANKAR VV, LUCAS MS, STOCK W et al.: Phase I study of escalated thrice-weekly dosing of Hu 1 D10 in chronic lymphocytic leukaemia/small lymphocytic lymphoma: minimal toxicity and early observation of in vivotumour cell apoptosis. Proc. Am. Soc. Clio. Oncol (2002) 21:268a (abstract #1069).
   Google Scholar
• SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al.: Selective ablation of acute myeloid leukaemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93:3678–3684.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, LARSON RA, STADTMAUER EA et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J. Clio. Oncol (2001) 19:3244–3254.
   PubMed Web of Science ®Google Scholar
• MACKLIS RM, KINSEY BM, KASSIS AT et al.: Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988) 240:1024–1026.
   PubMed Web of Science ®Google Scholar
• MCDEVITT MR, SGOUROS G, FINN RD et al: Radioimmunotherapy with alpha-emitting nuclides. Ear: I Nucl. Med. (1998) 25:1341–1351.
   PubMedGoogle Scholar
• MACKLIS RM, KAPLAN RD, FERRARA JL et al.: Alpha particle radioimmunotherapy: Animal models and clinical prospects. Int. J. Radiat. Oncol Biol. Phys. (1989) 16:1377–1387.
   PubMed Web of Science ®Google Scholar
• MEREDITH R, LOBUGLIO AT, KNOX S et al.: A Phase I study evaluating the pharmacokinetics of antiCD20 fusion protein, synthetic clearing agent and 9°yttrium DOTA-biotin. Proc. Am. Soc. Clio. Oncol (2002) 21:3a (abstract #9).
   Google Scholar
• ZHANG M, YAO Z, GARMESTANI K et al.: Pretargeting radioimmunotherapy of a murine model of adult T cell leukaemia with the a-emitting radionuclide, bismuth 213. Blood (2002) 100:208–216.
   PubMed Web of Science ®Google Scholar
• LOPES DE MENEZES DE, PILARSKI LM, ALLEN TM: ha vitro and in vivo targeting of immunoliposomal doxorubicin to human B cell lymphoma. Cancer Res. (1998) 58:3320–3330.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Radiolabled antiCD20 monoclonal antibodies for the treatment of B cell lymphoma. Clio. Oncol (2002) 20:3545–3557.
   PubMed Web of Science ®Google Scholar
• •A review comparing two radiolabelled anti-CD20 mAbs, 9°Y ibriturnomab tituietan and 1311 tositumomab.
   Google Scholar
• CHESON BD (ed): Monoclonal antibody therapy of hematologic malignancies. Darwin Scientific Publishing Ltd, (2001), Abingdon, United Kingdom
   Google Scholar
• •An informative book updating the results of mAb therapy for haematologic malignancies.
   Google Scholar
• ROSEN ST (ed): Current and ongoing clinical development of immunotherapy in B cell malignancies. Semin. Oncol (2002) 29 (Suppl. 2):1–125.
   PubMed Web of Science ®Google Scholar
• •A proceeding of a conference which was held in January 2001, focusing on the development of rituximab.
   Google Scholar
• ILLIDGE TM, JOHNSON PWM: The emerging role of radioimmunotherapy in haematological malignancies. Br. Haematol (2000) 108:679–688.
   PubMed Web of Science ®Google Scholar